{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T12:05:39Z","timestamp":1784030739496,"version":"3.55.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2006,3,1]],"date-time":"2006-03-01T00:00:00Z","timestamp":1141171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2006,3]]},"DOI":"10.1016\/j.clinthera.2006.03.008","type":"journal-article","created":{"date-parts":[[2006,6,7]],"date-time":"2006-06-07T21:13:22Z","timestamp":1149714802000},"page":"352-364","source":"Crossref","is-referenced-by-count":64,"title":["A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee"],"prefix":"10.1016","volume":"28","author":[{"given":"Alan","family":"Kivitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Ahdieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley S.","family":"Galer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2006.03.008_bib1","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1023\/A:1012057403159","article-title":"The undertreatment of pain: Scientific, clinical, cultural, and philosophical factors","volume":"4","author":"Resnik","year":"2001","journal-title":"Med Health Care Philos"},{"key":"10.1016\/j.clinthera.2006.03.008_bib2","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1002\/1529-0131(200009)43:9<1905::AID-ANR1>3.0.CO;2-P","article-title":"Recommendations for the medical management of osteoarthritis of the hip and knee","volume":"43","author":"American College of Rheumatology Subcommittee on Osteoarthritis Guidelines","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2006.03.008_bib3","series-title":"Guideline for the Management of Pain in Osteoarthritis, Rheumatoid Arthritis and Juvenile Chronic Arthritis","author":"American Pain Society","year":"2002"},{"key":"10.1016\/j.clinthera.2006.03.008_bib4","first-page":"764","article-title":"Double blind randomized placebo control trial of controlled release codeine in the treatment of osteoarthritis of the hip or knee","volume":"27","author":"Peloso","year":"2000","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clinthera.2006.03.008_bib5","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/S0885-3924(02)00383-4","article-title":"Efficacy and safety of a oncedaily morphine formulation in chronic, moderate-to-severe osteoarthritis pain: Results from a randomized, placebo-controlled, double-blind trial and an open-label extension trial","volume":"23","author":"Caldwell","year":"2002","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.clinthera.2006.03.008_bib6","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1097\/01.ajp.0000146215.86038.38","article-title":"Treatment of persistent pain associated with osteoarthritis with controlled-release oxycodone tablets in a randomized controlled clinical trial","volume":"21","author":"Markenson","year":"2005","journal-title":"Clin J Pain"},{"key":"10.1016\/j.clinthera.2006.03.008_bib7","first-page":"2196","article-title":"A comparison of oncedaily tramadol with normal release tramadol in the treatment of pain in osteoarthritis","volume":"29","author":"Adler","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clinthera.2006.03.008_bib8","first-page":"451","article-title":"Osteoarthritis antirheumatic drug trials. III. Setting the delta for clinical trials-results of a consensus development (Delphi) exercise","volume":"19","author":"Bellamy","year":"1992","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clinthera.2006.03.008_bib9","doi-asserted-by":"crossref","first-page":"955","DOI":"10.2165\/00003495-200161070-00005","article-title":"Strategies for the treatment of cancer pain in the new millennium","volume":"61","author":"Ripamonti","year":"2001","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2006.03.008_bib10","first-page":"7752","article-title":"The mu opiate receptor as a candidate gene for pain: Polymorphisms, variations in expression, nociception, and opiate responses","volume":"96","author":"Uhl","year":"1999"},{"key":"10.1016\/j.clinthera.2006.03.008_bib11","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1200\/JCO.2001.19.9.2542","article-title":"Strategies to manage the adverse effects of oral morphine: An evidencebased report","volume":"19","author":"Cherny","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2006.03.008_bib12","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1200\/JCO.2002.20.1.348","article-title":"Opioid rotation in the management of refractory cancer pain","volume":"20","author":"Indelicato","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2006.03.008_bib13","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1213\/00000539-200004000-00029","article-title":"Opioid substitution to improve the effectiveness of chronic noncancer pain control: A chart review","volume":"90","author":"Quang-Cantagrel","year":"2000","journal-title":"Anesth Analg"},{"key":"10.1016\/j.clinthera.2006.03.008_bib14","series-title":"American Pain Society 21st Scientific Meeting","article-title":"Retrospective assessment of frequency of dosing of sustained re lease opiate preparations","author":"Adams","year":"2005"},{"key":"10.1016\/j.clinthera.2006.03.008_bib15","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1021\/jm000381r","article-title":"Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via sitedirected mutagenesis of opioid receptors: Exploring the\u201caddress\u201d recognition locus","volume":"44","author":"Metzger","year":"2001","journal-title":"J Med Chem"},{"key":"10.1016\/j.clinthera.2006.03.008_bib16","first-page":"116","article-title":"The analgesic equivalence to morphine and relative side action liability of oxymorphone (4-hydroxydihydromorphinone)","volume":"125","author":"Eddy","year":"1959","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.clinthera.2006.03.008_bib17","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1592\/phco.24.5.468.33347","article-title":"Pharmacokinetics and dose-proportionality of oxymorphone extended release and its metabolites: Results of a randomized crossover study","volume":"24","author":"Adams","year":"2004","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clinthera.2006.03.008_bib18","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1177\/0091270004266487","article-title":"Efficacy of oxymorphone extended release in postsurgical pain: A ran domized clinical trial in knee arthroplasty","volume":"44","author":"Ahdieh","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2006.03.008_bib19","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1185\/030079904125003854","article-title":"Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: A randomizedcontrolled study","volume":"20","author":"Gabrail","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2006.03.008_bib20","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/01.mjt.0000139442.65914.f9","article-title":"Safety, tolerability, and effectiveness of oxymorphone extended release for moderate to severe osteoarthritis pain: A oneyear study","volume":"12","author":"McIlwain","year":"2005","journal-title":"Am J Ther"},{"key":"10.1016\/j.clinthera.2006.03.008_bib21","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jpain.2004.09.005","article-title":"Efficacy and safety of oxymorphone extended release in chronic low back pain: Results of a randomized, double-blind, placebo- and activecontrolled phase III study","volume":"6","author":"Hale","year":"2005","journal-title":"J Pain"},{"key":"10.1016\/j.clinthera.2006.03.008_bib22","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1526-4637.2005.00057.x","article-title":"Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: Results of a randomized, double-blind, placebo- and activecontrolled phase III trial","volume":"6","author":"Matsumoto","year":"2005","journal-title":"Pain Med"},{"key":"10.1016\/j.clinthera.2006.03.008_bib23","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1136\/ard.17.4.388","article-title":"Osteoarthritis and disk degeneration in an urban population","volume":"17","author":"Kellgren","year":"1958","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2006.03.008_bib24","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/BF03016561","article-title":"Recurrent seizure activity after epidural morphine in a post-partum woman","volume":"52","author":"Shih","year":"2005","journal-title":"Can J Anaesth"},{"key":"10.1016\/j.clinthera.2006.03.008_bib25","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1093\/bja\/60.6.733","article-title":"Grand mal seizure after extradural morphine analgesia","volume":"60","author":"Borgeat","year":"1988","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.clinthera.2006.03.008_bib26","series-title":"Presented at the American College of Rheumatology ACR\/ARHP 67th Annual Scientific Meeting","article-title":"A placebo-and active-controlled trial of oxymorphone extended re lease for moderate to severe pain in osteoarthritis of the knee and hip","author":"Matsumoto","year":"2003"},{"key":"10.1016\/j.clinthera.2006.03.008_bib27","series-title":"Guideline for the Clinical Evaluation of Analgesic Drugs","year":"1992"},{"key":"10.1016\/j.clinthera.2006.03.008_bib28","first-page":"1833","article-title":"Validation study of WOMAC: A health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy inpatients with osteoarthritis of the hip or knee","volume":"15","author":"Bellamy","year":"1988","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clinthera.2006.03.008_bib29","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual frame work and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"key":"10.1016\/j.clinthera.2006.03.008_bib30","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jpainsymman.2003.11.006","article-title":"Efficacy and safety of extendedrelease, once-daily tramadol in chron ic pain: A randomized 12-week clinical trial in osteoarthritis of the knee","volume":"28","author":"Babul","year":"2004","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.clinthera.2006.03.008_bib31","series-title":"International Conference on Harmonisation, Medical Dictionary for Regulatory Activities (MedDRA)","year":"2004"},{"key":"10.1016\/j.clinthera.2006.03.008_bib32","first-page":"444","article-title":"Osteoarthritis antirheumatic drug trials. II. Tables for calculating sam ple size for clinical trials","volume":"19","author":"Bellamy","year":"1992","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clinthera.2006.03.008_bib33","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2307\/2530666","article-title":"Testing the statistical certainty of a response to increasing doses of a drug","volume":"41","author":"Tukey","year":"1985","journal-title":"Biometrics"},{"key":"10.1016\/j.clinthera.2006.03.008_bib34","series-title":"Statistical Methods for Rates and Populations","author":"Fleiss","year":"2003"},{"key":"10.1016\/j.clinthera.2006.03.008_bib35","first-page":"862","article-title":"Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal antiinflammatory drugs: A double blind, randomized, multicenter, placebo controlled trial","volume":"26","author":"Caldwell","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clinthera.2006.03.008_bib36","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.3122\/jabfm.17.suppl_1.S1","article-title":"Pain management by the family physician: The family practice pain education project","volume":"17","author":"Bope","year":"2004","journal-title":"J Am Board Fam Pract"},{"key":"10.1016\/j.clinthera.2006.03.008_bib37","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/archinte.160.6.853","article-title":"Around-the-clock, controlled release oxycodone therapy for osteoarthritis-related pain: Placebocontrolled trial and long-term evaluation","volume":"160","author":"Roth","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clinthera.2006.03.008_bib38","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/00002508-200409000-00012","article-title":"Sustainedrelease oxycodone dosing survey of chronic pain patients","volume":"20","author":"Marcus","year":"2004","journal-title":"Clin J Pain"},{"key":"10.1016\/j.clinthera.2006.03.008_bib39","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0304-3959(97)00093-6","article-title":"The intrinsic antinociceptive effects of oxycodone appear to be kappa-opioid receptor mediated","volume":"73","author":"Ross","year":"1997","journal-title":"Pain"},{"key":"10.1016\/j.clinthera.2006.03.008_bib40","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0169-409X(00)00104-6","article-title":"Microdialysis in the study of drug transporters in the CNS","volume":"45","author":"Sawchuk","year":"2000","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.clinthera.2006.03.008_bib41","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/j.1399-6576.2005.00772.x","article-title":"Genetic variability and clinical efficacy of morphine","volume":"49","author":"Klepstad","year":"2005","journal-title":"Acta Anaesthesiol Scand"},{"key":"10.1016\/j.clinthera.2006.03.008_bib42","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.clpt.2003.08.011","article-title":"Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine","volume":"74","author":"Kharasch","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2006.03.008_bib43","series-title":"Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine","author":"Flockhart","year":"2005"},{"key":"10.1016\/j.clinthera.2006.03.008_bib44","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0009-9236(98)90051-0","article-title":"Effects of blocking CYP2D6 on the pharmacokinetics and pharmacody namics of oxycodone","volume":"64","author":"Heiskanen","year":"1998","journal-title":"Clin Pharmacol Ther."},{"key":"10.1016\/j.clinthera.2006.03.008_bib45","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2165\/00003088-199937010-00002","article-title":"Pharmacokinetics of opioids in liver disease","volume":"37","author":"Tegeder","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2006.03.008_bib46","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1046\/j.1440-1681.2000.03293.x","article-title":"Bedside perspectives on the use of opioids: Transferring results of clinical research into practice","volume":"27","author":"Ravenscroft","year":"2000","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.clinthera.2006.03.008_bib47","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1124\/dmd.32.4.447","article-title":"Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes","volume":"32","author":"Lalovic","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.clinthera.2006.03.008_bib48","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1177\/0091270004271969","article-title":"Oxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathways","volume":"45","author":"Adams","year":"2005","journal-title":"J Clin Pharmacol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291806000737?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291806000737?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,19]],"date-time":"2019-04-19T07:22:05Z","timestamp":1555658525000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291806000737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,3]]}},"alternative-id":["S0149291806000737"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2006.03.008","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2006,3]]}}}